Successful treatment with liposomal amphotericin B in two patients with persisting fungemia

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
J P SculierF Meunier

Abstract

Two granulocytopenic patients in whom fungemia persisted despite therapy with deoxycholate amphotericin B were subsequently successfully treated by daily intravenous administration of amphotericin B entrapped in sonicated liposomes made of egg yolk lecithin, cholesterol and stearylamine in a molar ratio of 4:3:1. High serum concentrations of amphotericin B could be maintained in both patients during therapy with liposomal amphotericin B and were associated with high in vitro antifungal activity. Liposomal amphotericin B was tolerated much better than the deoxycholate preparation. These findings suggest that the liposomal amphotericin B preparation is superior in the treatment of fungemia in granulocytopenic patients, and that randomized trials are warranted.

References

Dec 1, 1987·Antimicrobial Agents and Chemotherapy·R L HopferG Lopez-Berestein
Jan 1, 1988·Antimicrobial Agents and Chemotherapy·M S Saag, W E Dismukes
Jan 1, 1988·Annals of the New York Academy of Sciences·F MeunierJ Klastersky
Apr 1, 1988·Clinical Microbiology Reviews·R A Fromtling
Mar 1, 1988·European Journal of Cancer & Clinical Oncology·J P SculierJ Klastersky
Feb 1, 1986·European Journal of Clinical Microbiology·F Meunier
Aug 7, 1987·Journal of Chromatography·C BrassinneF Meunier
Feb 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Lopez-BeresteinK Mehta
Jan 1, 1985·Journal of Inherited Metabolic Disease·S KrywawychD P Brenton
Oct 1, 1969·The Journal of Infectious Diseases·D D Bindschadler, J E Bennett
Sep 1, 1981·The American Journal of Medicine·F Meunier-CarpentierD Armstrong

❮ Previous
Next ❯

Citations

Feb 1, 1996·International Journal of Antimicrobial Agents·F Meunier
Aug 1, 1991·Journal of Internal Medicine·M BjörkholmA M Udén
Apr 9, 1998·Journal of Microencapsulation·M GulatiM Singh
May 1, 1994·The Journal of Infection·F Meunier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.